New Dual-Target CAR-T therapy offers hope for tough lymphoma
NCT ID NCT05800977
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This study tests a new treatment called C-CAR039 (Prizlon-cel) for people with large B-cell lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack two targets (CD19 and CD20) on cancer cells. The study has two phases: first to find the safest dose, then to see how well it shrinks tumors. About 112 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
COMPLETEDBeijing, China
-
Beijing GoBroad Hospital
RECRUITINGBeijing, China
Contact
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, China
Contact
-
Chinese Academy of Medical Sciences Hematology Hospital
RECRUITINGTianjin, China
Contact
Contact
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, China
Contact
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, China
Contact
-
Henan Cancer Hospital
RECRUITINGZhengzhou, China
Contact
-
Jiangsu Province Hospital
RECRUITINGNanjing, China
Contact
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, China
Contact
-
Peking University Third Hospital
RECRUITINGBeijing, China
Contact
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Contact
-
The First Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, China
Contact
-
Tianjin Medical University Cancer Institute& Hospital
RECRUITINGTianjin, China
Contact
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, China
Contact
Conditions
Explore the condition pages connected to this study.